Intercepting the NF1 course through early MEK inhibition
Authors:
- Nicolas AndréNicolas André
- Laura FertittaLaura Fertitta
- Pierre LeblondPierre Leblond
- Mona Amini-AdleMAMona Amini-Adle
- Pierre WolkensteinPierre Wolkenstein
Open Access
- 30 September 2026
- journal article
- Published by Elsevier in The Innovation
- Vol. 7 (11)
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 studyThe Lancet, 2025
- Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutationNature Medicine, 2023
- Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1Neurology Genetics, 2021
- Selumetinib in Children with Inoperable Plexiform NeurofibromasNew England Journal of Medicine, 2020
- Neurofibromatosis type 1Nature Reviews Disease Primers, 2017